Trials / Completed
CompletedNCT03014479
Study of the QOL Evaluation of Trelagliptin in Patients With Type 2 Diabetes Mellitus
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 219 (actual)
- Sponsor
- Takeda · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess the reduction in treatment burden during 12 weeks of trelagliptin administration in patients with type 2 diabetes on diet and exercise therapy only.
Detailed description
The purpose of this study is to assess the reduction in treatment burden during 12 weeks of trelagliptin administration in patients with type 2 diabetes on diet and exercise therapy only. Eligible participants will be randomized to either the study drug (trelagliptin) group or the comparative drug (daily DPP-4 inhibitor) group. Treatment burden will be assessed using Diabetes Therapy Related -QOL (DTR-QOL) questionnaire and Diabetes Treatment Satisfaction Questionnaire (DTSQ).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Trelagliptin | Trelagliptin 100 mg or 50 mg |
| DRUG | Daily DPP-4 inhibitor | Alogliptin, anagliptin, linagliptin, saxagliptin, sitagliptin, teneligliptin or vildagliptin |
Timeline
- Start date
- 2017-02-18
- Primary completion
- 2017-10-21
- Completion
- 2017-10-21
- First posted
- 2017-01-09
- Last updated
- 2023-12-22
- Results posted
- 2019-02-25
Locations
27 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT03014479. Inclusion in this directory is not an endorsement.